<p>Ovid Therapeutics Inc. held a special meeting of stockholders on December 11, 2025. Stockholders approved an increase in authorized shares of common stock from 125,000,000 to 315,000,000. Approval was also granted for the issuance of shares of common stock upon the conversion of Series B Preferred Stock and the exercise of related warrants. In addition, the issuance and sale of preferred stock and warrants to the Chief Executive Officer was approved. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001636651-25-000017), on December 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

OVID

<p>Ovid Therapeutics Inc. held a special shareholder meeting on December 11, 2025, where stockholders approved an increase in authorized common stock shares from 125 million to 315 million. They also approved the issuance of shares upon conversion of Series B Preferred Stock and related warrants, and the issuance and sale of preferred stock and warrants to the CEO.</p>

Ovid Therapeutics Inc. Held Special Shareholder Meeting